			Home About us Contact

Prosthetic Implants (prosthetic + implant)

Distribution by Scientific Domains

Medical Sciences	50%

Selected Abstracts

Prosthetic implants for hernia repair

BRITISH JOURNAL OF SURGERY (NOW INCLUDES EUROPEAN JOURNAL OF SURGERY), Issue 12 2003
V. Schumpelick
The future of mesh [source]

Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure

HAEMOPHILIA, Issue 6 2002
V. Mishra
Summary. As more and more nations are scrutinizing their health care costs, attention has been focused on high-cost low-density disease. Assessment of actual total cost of care for haemophilia and its positive outcome becomes essential to justify support for these patients. In this study, we assessed hospital cost and diagnosis-related group (DRG) reimbursement for patients undergoing elective orthopaedic surgical procedures from May 1999 to December 1999. Hospital cost was assessed by a prospective microcost-analysis method. To identify real hospital costs, we performed registration of preoperative phase, operative phase and 1-year follow-up costs. Hospital cost included personnel costs and costs for clinical and laboratory procedures, blood products, prosthetic implants, coagulation factor concentrates and drugs. These data were compared with hospital DRG reimbursement. We included nine consecutive patients, with a mean age 38 years (19,54 years) who had had 10 major orthopaedic surgical procedures performed during the study period. Six patients had haemophilia A, two had haemophilia B and one had factor VII deficiency. Data analysis showed a mean cost of US$ 54 201 (range US$ 25 795,105 479; 1US$ = 8.5 NOK). The average actual hospital revenue (50% DRG reimbursement + income related to length of stay) was $4730 (range $ 1 308,13 601). Our study confirms that orthopaedic surgery in patients with severe bleeding disorders puts the hospital to a considerable expense. Activity-based financing, as used in Norway, does not provide a proper reimbursement for this part of the haemophilia care. [source]

Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis

JOURNAL OF ORTHOPAEDIC RESEARCH, Issue 2 2002
J. Jeffrey Goater
Aseptic loosening of prosthetic implants remains a serious orthopaedic problem and the greatest limitation to total joint arthroplasty. Central to the etiology of aseptic loosening is periprosthetic osteolysis at the bone-implant interface, which is caused by wear debris-induced inflammation. This inflammation produces the critical osteoclast differentiation factor RANKL, which directly stimulates osteoclastogenesis and osteoclastic bone resorption. A dominant factor known to counteract this process is the natural RANKL receptor antagonist protein OPG. Here we explore the potential of ex vivo OPG gene therapy for aseptic loosening by evaluating the efficacy of stably transfected fibroblast-like synoviocytes (FLS) expressing OPG in preventing wear debris-induced osteoclastogenesis, in a mouse calvaria model. Although the stably transfected fibroblasts produced small amounts of OPG (0.3 ng/ml/72 h/106 cells), this protein was very effective in preventing osteoclastic resorption as determined in a bone wafer assay. More importantly, implantation of 107 FLS,OPG, together with 30 mg of Ti wear debris, onto the calvaria of mice, completely inhibited osteoclastogenesis 3 days after surgery. Animals given FLS-LacZ control cells, which persisted for 3 days as determined by X-gal staining, together with the Ti particles, had a 6-fold increase in osteoclastogenesis compared to controls without Ti. This increased osteoclastogenesis was completely inhibited by the FLS-OPG, as osteoclast numbers in the calvaria of these animals were similar to that seen in the SHAM controls. © 2002 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved. [source]

Pressureless Sintering t -zirconia@,-Al2O3 (54 mol%) Core,Shell Nanopowders at 1120°C Provides Dense t -Zirconia-Toughened ,-Al2O3 Nanocomposites

JOURNAL OF THE AMERICAN CERAMIC SOCIETY, Issue 3 2010
Min Kim
Zirconia-toughened alumina (ZTA) is of growing importance in a wide variety of fields exemplified by ZTA prosthetic implants. Unfortunately, ZTA composites are generally difficult to process because of the need to preserve the tetragonal zirconia phase in the final dense ceramic, coincident with the need to fully densify the ,-Al2O3 component. We report here that liquid-feed flame spray pyrolysis of mixtures of metalloorganic precursors of alumina and zirconia at varying compositional ratios provide access in one step to core,shell nanoparticles, wherein the shell is ,-Al2O3 and the core is a perfect single crystal of tetragonal (t -) zirconia. Pressureless sintering studies provided parameters whereby these nanopowder compacts could be sintered to full density (>99%) at temperatures just above 1100°C converting the shell component to ,-Al2O3 but preserving the t -ZrO2 without the need for any dopants. The final average grain sizes of these sintered compacts are ,200 nm. The resulting materials exhibit the expected response to mechanical deformation with the subsequent production of monoclinic ZrO2. These materials appear to offer a low-temperature, low-cost route to fine-grained ZTA with varied Al2O3:t -ZrO2 compositions. [source]